Plasma-derived exosomes in acute myeloid leukemia for detection of minimal residual disease: are we ready?

Expert Review of Molecular Diagnostics

Volumn 16, Issue 6, 2016, Pages 623-629

  Boyiadzis, Michael ^a   Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

acute myeloid leukemia; biomarker; Exosomes; leukemia relapse; minimal residual disease

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BIOGENESIS; CLINICAL ASSESSMENT; EXOSOME; HUMAN; ISOLATION; LEUKEMIA RELAPSE; MINIMAL RESIDUAL DISEASE; PLASMA; STANDARD; ACUTE MYELOID LEUKEMIA; BLOOD; METABOLISM; MOLECULAR DIAGNOSIS; PROCEDURES; STANDARDS;

BIOMARKERS, TUMOR; EXOSOMES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 84964461903     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1080/14737159.2016.1174578     Document Type: Article

References (40)

1. H.Dombret, C.Gardin An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53–61.
2. F.Ferrara, C.A.Schiffer. Acute myeloid leukaemia in adults. Lancet. 2013;381(9865):484–495.
3. S.A.Buckley, F.R.Appelbaum, R.B.Walter. Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplant. 2013;48(5):630–641.
4. E.Paietta. Should minimal residual disease guide therapy in AML? Best Pract Res Clin Haematol. 2015;28(2–3):98–105.
5. E.Paietta. Minimal residual disease in acute myeloid leukemia: coming of age. Hematol/Educ Program Am Soc Hematol Am Soc Hematol Educ Program. 2012;2012:35–42.
6. D.Grimwade, S.D.Freeman. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”? Hematol/Educ Program Am Soc Hematol Am Soc Hematol Educ Program. 2014;2014(1):222–233.
7. E.Paietta. Assessing minimal residual disease (MRD) in leukemia: a changing definition and concept? Bone Marrow Transplant. 2002;29(6):459–465.
8. P.Hokland, H.B.Ommen, M.P.Mulé, et al. Advancing the minimal residual disease concept in acute myeloid leukemia. Semin Hematol. 2015;52(3):184–192.
9. A.Ivey, R.K.Hills, M.A.Simpson, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374(5):422–433.•• This manuscriopt defines the role of NPM1-mutated transcripts and MRD in AML.
10. S.Keller, J.Ridinger, A.-K.Rupp, et al. Body fluid derived exosomes as a novel template for clinical diagnostics. J Transl Med. 2011;9(1):86.
11. E.van der Pol, A.N.Böing, P.Harrison, et al. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev. 2012;64(3):676–705.
12. M.J.Szczepanski, M.Szajnik, A.Welsh, et al. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica. 2011;96(9):1302–1309.• This is one of the first manuscrips reporting that exosomes isolated from plasma of AML patients modulate functions of human immune cells.
13. G.Raposo, W.Stoorvogel. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–383.
14. E.Cocucci, J.Meldolesi. Ectosomes and exosomes: shedding the confusion between extracellular vesicles. Trends Cell Biol. 2015;25(6):364–372.•• An up-to-date, comprehensive review of the biogenesis of EVs, including exosomes.
15. Z.Andreau, M.Yanez-Mo. Tetraspanins in extracellular vesicle formation and function. Front Immunol. 2014;5:1–12.
16. C.Théry, L.Zitvogel, S.Amigorena. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569–579.
17. L.A.Mulcahy, R.C.Pink, D.R.Carter. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 2014;3:24641.
18. S.Atay, A.K.Godwin. Tumor-derived exosomes: A message delivery system for tumor progression. Commun Integr Biol. 2014;7(1):e28231.
19. M.Boyiadzis, T.L.Whiteside. Information transfer by exosomes: a new frontier in hematologic malignancies. Blood Rev. 2015;29(5):281–290.
20. D.D.Taylor, S.Shah. Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes. Methods. 2015;87:3–10.•• A current review of various methodologies available for EVs isolation.
21. L.Muller, C.-S.Hong, D.B.Stolz, et al. Isolation of biologically-active exosomes from human plasma. J Immunol Methods. 2014;411:55–65.
22. J.L.Welton, J.P.Webber, L.-A.Botos, et al. Ready-made chromatography columns for extracellular vesicle isolation from plasma. J Extracell Vesicles. 2015;4:27269.
23. C.Hong, S.Funk, L.Muller, et al. Isolation of biologically-active and morphologically-intact exosomes from plasma of patients with cancer. J Extracell Vesicles. 2016;5:29289.
24. C.S.Hong, L.Muller, M.Boyiadzis, et al. Isolation and characterization of CD34+ blast-derived exosomes in acute myeloid leukemia. PLoS One. 2014;9(8):e103310.• This is a proof-of- concept paper in which the authors report on the isolation and molecular as well functional characterization of blast-derived exosomes from plasma of CD34+ AML patients at diagnosis.
25. C.Villarroya-Beltri, F.Baixauli, C.Gutiérrez-Vázquez, et al. Sorting it out: regulation of exosome loading. Semin Cancer Biol. 2014;28:3–13.
26. M.Colombo, C.Moita, G.van Niel, et al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J Cell Sci. 2013;126(Pt 24):5553–5565.
27. S.Boukouris, S.Mathivanan. Exosomes in bodily fluids are a highly stable resource of disease biomarkers. Proteomics Clin Appl. 2015;9(3–4):358–367.
28. C.Kahlert, R.Kalluri. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl). 2013;91(4):431–437.
29. S.A.Melo, L.B.Luecke, C.Kahlert, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177–182.•• This is a high impact high visibility paper demonstrating that cancer-cell-derived exosomes serve as a non-invasive siagnostic and screening tool for detection of pancreatic cancer in man.
30. C.-S.Hong, L.Muller, T.L.Whiteside, et al. Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia. Front Immunol. 2014;5:160.
31. M.H.C.Boyiadzis, T.L.Hong CS, Whiteside. Evidence for the role of biologically active exosomes in acute myeloid leukemia relapse. Blood. 2015;126(23).
32. A.Wojtuszkiewicz, G.J.Schuurhuis, F.L.Kessler, et al. Exosomes secreted by apoptosis-resistant acute myeloid leukemia (AML) blasts harbor regulatory network proteins potentially involved in antagonism of apoptosis. Mol Cell Proteomics. 2016;15(4):1281–1298.
33. J.Huan, N.I.Hornick, M.J.Shurtleff, et al. RNA trafficking by acute myelogenous leukemia exosomes. Cancer Res. 2013;73(2):918–929.
34. N.I.Hornick, J.Huan, B.Doron, et al. Serum exosome microRNA as a minimally-invasive early biomarker of AML. Sci Rep. 2015;5:11295.•• The authors report that leukemic blasts and the marrow stroma serve as a source for exosomal miRNA in AML and serve as a platform for development of exosomal miRNA as a biomarker for prospective monitoring and early detection of AML recurrence.
35. T.Katsuda, N.Kosaka, T.Ochiya. The roles of extracellular vesicles in cancer biology: toward the development of novel cancer biomarkers. Proteomics. 2014;14(4–5):412–425.
36. T.L.Whiteside. The potential of tumor-derived exosomes for noninvasive cancer monitoring. Expert Rev Mol Diagn. 2015;15:1293–1310.
37. S.J.Gould, G.Raposo. As we wait: coping with an imperfect nomenclature for extracellular vesicles. J Extracell Vesicles. 2013;2:20389.
38. Z.Andreu, M.Yanez-Mo. Tetraspanins in extracellular vesicle formation and function. Front Immunol. 2014;5:442.
39. J.Skog, T.Wurdinger, S.van Rijn, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470–1476.
40. L.M.McShane, D.G.Altman, W.Sauerbrei, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97(16):1180–1184.